NEUROCRINE BIOSCIENCES, INC. 2020股权激励计划于2020年3月16日获报酬委员会通过，并于2020年5月19日获股东批准。并由2022年3月14日获报酬委员会修订，2022年5月18日获股东批准。且由2023年3月24日获报酬委员会修订，2023年5月17日获股东批准。再由2024年3月18日获报酬委员会修订，2024年5月22日获股东批准。并由2024年9月13日获报酬委员会修订，终止日期为2030年3月15日。 ( 1. 一般。 (a) 继位并续前计划。 该计划是前计划的继位并续续。 在生效日期的隔天，(i)将不再在前计划下授予任何附加奖励; (ii)前计划的可用储备，再加上任何可从时间至时间提供的前计划的返还股份，将可用于根据本计划授予的奖励发行; 及(iii)所有前计划奖励将继续受前计划条款约束(但任何前计划的返还股份将可用于根据本计划授予的奖励发行)。根据本计划授予的所有奖励将受本计划条款约束。(b) 计划目的。 公司借由该计划旨在担保并留住员工、董事和顾问的服务，为这些人提供刺激以为公司和任何联属公司的成功而尽最大努力，并为这些人提供一个机会以受益于普通股价值的增加，通过授予奖励。 (c) 可用奖项。 该计划提供以下奖项的授予:(i)激励性股票期权; (ii)非统计股票期权; (iii) SARs; (iv)限制性股票奖项; (v) RSU奖项; (vi)表现奖项; 和(vii)其他奖项。(d) 采用日期。 该计划将于采用日期生效。 在采用日期之前不得根据本计划授予任何奖项。在生效日期之前所授予的任何奖项,若根据适用的税收、证券和监管规则要求的股东批准迅速收到,并满足任何其他遵循要求。 (2. 股份受计划约束。 (a) 股份储备。根据第2(a)(iii)条款进行的任何调整，根据第2(b)条款进行的任何调整以实施任何资本调整，可以发行的普通股股份总数不得超过以下总和:(i)前计划的可用储备;(ii)在2020年年会上批准的额外330万股;(iii)在2022年年会上批准的额外590万股;(iv)在2023年年会上批准的额外660万股;(v)在2024年年会上批准的额外363.5万股;和(vi)如有的前期计划返还股份数量 (如有，随时间提供)。(ii) 根据第2(b)条款，根据本计划发行的普通股可用于发行的股数将按以下方式进行减少:(A)根据本计划授予的重估奖项发行的每一股普通股，将减少一股;(B)在2022年5月18日以前根据本计划授予的每一股普通股，将减少一股;(C)在2022年5月18日后根据本计划授予的每一股普通股，将减少2.13股。 (iii) 根据第2(b)条款，根据本计划发行的普通股可用于发行的股数将增加( A )根据具体获利奖项受到的前计划返还股份或2020年计划返还股份(在第2(b)(iii)(1) ）对重估奖项;(B)在2022年5月18日以前返回到计划的每一股普通股，每一股普通股，将增加一股;(C)根据2022年5月18日后返回到计划的每一股普通股的每一股普通股，将增加2.13股。(b) 股份储备运作。 (i) 限制适用于根据奖项发行的股份。 为清晰起见，股份储备是可能根据奖项发行的普通股股份数量限制，并不限制奖项的授予，但公司将随时保留足够的普通股股份，以满足根据此类奖项发行股份的义务。可能会依据驳二资列 (1)、旧约列的契约，为骡子; ３点) 普通股配额不足，予英人。(ii) 行动不构成发行股份并不会减少股份储备。 下列行为不会导致根据计划发行普通股，因此也不会减少受股份储备约束的普通股的数量并可根据计划发行:(1)任何奖项的部分到期或终止而未发行所涵盖的股份;(2)任何奖项支付的粒现金结算;(即，参与者获得现金而不是普通股)。
不得低于授予该奖励之日期的公平市值的100％。尽管如前所述，如果采用或替代其他选择权或股票增值权，并且符合第409A条和适用时，可以授予具有低于授予该奖项之日期的公平市值100％的行使价格或行使价格的选择权或SAR 424(a)的法典条款
参与者将不具有投票权或其他股东的任何权利，关于 RSU 奖励，直到实际发行股份以解决已经授予的 RSU 奖励为止。
307473618 v2 13. need not be identical), including the time or times when a person will be permitted to receive an issuance of Common Stock or other payment pursuant to an Award; (5) the number of shares of Common Stock or cash equivalent with respect to which an Award will be granted to each such person; and (6) the Fair Market Value applicable to an Award. (ii) To construe and interpret the Plan and Awards granted under it, and to establish, amend and revoke rules and regulations for its administration. The Board, in the exercise of this power, may correct any defect, omission or inconsistency in the Plan or in any Award Agreement, in a manner and to the extent it deems necessary or expedient to make the Plan or Awards fully effective. (iii) To settle all controversies regarding the Plan and Awards granted under it. (iv) To accelerate the time at which an Award may first be exercised or the time during which an Award or any part thereof will vest, notwithstanding the provisions in the Award Agreement stating the time at which it may first be exercised or the time during which it will vest. (v) To prohibit the exercise of any Option, SAR or other exercisable Award during a period of up to 30 days prior to the consummation of any pending stock dividend, stock split, combination or exchange of shares, merger, consolidation or other distribution (other than normal cash dividends) of Company assets to stockholders, or any other change affecting the shares of Common Stock or the share price of the Common Stock, including any Transaction, for reasons of administrative convenience. (vi) To suspend or terminate the Plan at any time. Suspension or termination of the Plan will not Materially Impair a Participant’s rights under any Award granted while the Plan is in effect unless (1) the Company requests the consent of the affected Participant, and (2) such Participant consents in writing. (vii) To amend the Plan in any respect the Board deems necessary or advisable; provided, however, that stockholder approval will be required for any such amendment to the extent required by Applicable Law. Except as provided above, a Participant’s rights under any Award granted before any amendment of the Plan will not be Materially Impaired by any such amendment unless (1) the Company requests the consent of the affected Participant, and (2) such Participant consents in writing. (viii) To submit any amendment to the Plan for stockholder approval. (ix) To approve forms of Award Agreements for use under the Plan and to amend the terms of any one or more Awards, including, but not limited to, amendments to provide terms more favorable to the Participant than previously provided in the Award Agreement, subject to any specified limits in the Plan that are not subject to Board discretion; provided, however, that a Participant’s rights under any Award will not be Materially Impaired by any such amendment unless (1) the Company requests the consent of the affected Participant, and (2) such Participant consents in writing. 307473618 v2 14. (x) Generally, to exercise such powers and to perform such acts as the Board deems necessary or expedient to promote the best interests of the Company and that are not in conflict with the provisions of the Plan or Awards. (xi) To adopt such procedures and sub-plans as are necessary or appropriate to permit and facilitate participation in the Plan by, or take advantage of specific tax treatment for Awards granted to, Employees, Directors or Consultants who are foreign nationals or employed outside the United States (provided that Board approval will not be necessary for immaterial modifications to the Plan or any Award Agreement to ensure or facilitate compliance with the laws of the relevant foreign jurisdiction). (c) Delegation to Committee. (i) General. The Board may delegate some or all of the administration of the Plan to a Committee or Committees. If administration of the Plan is delegated to a Committee, the Committee will have, in connection with the administration of the Plan, the powers theretofore possessed by the Board that have been delegated to the Committee, including the power to delegate to another Committee or a subcommittee of the Committee any of the administrative powers the Committee is authorized to exercise (and references in this Plan to the Board will thereafter be to the Committee or subcommittee, as applicable), subject, however, to such resolutions, not inconsistent with the provisions of the Plan, as may be adopted from time to time by the Board. Each Committee may retain the authority to concurrently administer the Plan with any Committee or subcommittee to which it has delegated its authority hereunder and may, at any time, revest in such Committee some or all of the powers previously delegated. The Board may retain the authority to concurrently administer the Plan with any Committee and may, at any time, revest in the Board some or all of the powers previously delegated. (ii) Rule 160亿3 Compliance. To the extent an Award is intended to qualify for the exemption from Section 16(b) of the Exchange Act that is available under Rule 160亿3 of the Exchange Act, the Award will be granted by the Board or a Committee that consists solely of two or more Non-Employee Directors, as determined under Rule 160亿3(b)(3) of the Exchange Act, and thereafter any action establishing or modifying the terms of the Award will be approved by the Board or a Committee meeting such requirements to the extent necessary for such exemption to remain available. (d) Effect of Board’s Decision. All determinations, interpretations and constructions made by the Board or any Committee in good faith will not be subject to review by any person and will be final, binding and conclusive on all persons. (e) Cancellation and Re-Grant of Awards. Except in connection with a Transaction, as provided in Section 6(a) relating to Capitalization Adjustments, or unless the stockholders of the Company have approved such an action within 12 months prior to such an event, neither the Board nor any Committee will have the authority to: (i) reduce the exercise or strike price of any outstanding Option or SAR; or (ii) cancel any outstanding Option or SAR that has an exercise or strike price greater than the then-current Fair Market Value in exchange for cash or other Awards under the Plan. 307473618 v2 15. (f) Delegation to an Officer. The Board or any Committee may delegate to one or more Officers the authority to do one or both of the following: (i) designate Employees who are not Officers to be recipients of Options and SARs (and, to the extent permitted by Applicable Law, other types of Awards) and, to the extent permitted by Applicable Law, the terms thereof; and (ii) determine the number of shares of Common Stock to be subject to such Awards granted to such Employees; provided, however, that the resolutions or charter adopted by the Board or any Committee evidencing such delegation will specify the total number of shares of Common Stock that may be subject to the Awards granted by such Officer and that such Officer may not grant an Award to himself or herself. Any such Awards will be granted on the applicable form of Award Agreement most recently approved for use by the Board or the Committee, unless otherwise provided in the resolutions approving the delegation authority. Notwithstanding anything to the contrary herein, neither the Board nor any Committee may delegate to an Officer who is acting solely in the capacity of an Officer (and not also as a Director) the authority to determine the Fair Market Value. 8. TAX WITHHOLDING. (a) Withholding Authorization. As a condition to acceptance of any Award, a Participant authorizes withholding from payroll and any other amounts payable to such Participant, and otherwise agrees to make adequate provision for, any sums required to satisfy any U.S. federal, state, local and/or foreign tax or social insurance contribution withholding obligations of the Company or an Affiliate, if any, which arise in connection with the exercise, vesting or settlement of such Award, as applicable. Accordingly, a Participant may not be able to exercise an Award even though the Award is vested, and the Company will have no obligation to issue shares of Common Stock subject to an Award, unless and until such withholding obligations are satisfied. (b) Satisfaction of Withholding Obligations. To the extent permitted by the terms of an Award Agreement, the Company may, in its sole discretion, satisfy any U.S. federal, state, local and/or foreign tax or social insurance contribution withholding obligations relating to an Award by any of the following means or by a combination of such means: (i) causing the Participant to tender a cash payment; (ii) withholding shares of Common Stock from the shares of Common Stock issued or otherwise issuable to the Participant in connection with the Award; (iii) withholding cash from an Award settled in cash; (iv) withholding payment from any amounts otherwise payable to the Participant; (v) by allowing a Participant to effectuate a “cashless exercise” pursuant to a program developed under Regulation t as promulgated by the Federal Reserve Board; or (vi) by such other method as may be set forth in the Award Agreement. (c) No Obligation to Notify or Minimize Taxes; No Liability to Claims. Except as required by Applicable Law, the Company has no duty or obligation to any Participant to advise such Participant as to the time or manner of exercising an Award. Furthermore, the Company has no duty or obligation to warn or otherwise advise such Participant of a pending termination or expiration of an Award or a possible period in which the Award may not be exercised. The Company has no duty or obligation to minimize the tax consequences of an Award to any Participant and will not be liable to any Participant for any adverse tax consequences to such Participant in connection with an Award. As a condition to accepting an Award, each Participant 307473618 v2 16. (i) agrees to not make any claim against the Company, or any of its Officers, Directors, Employees or Affiliates related to tax liabilities arising from such Award or other Company compensation and (ii) acknowledges that such Participant was advised to consult with his or her own personal tax, financial and other legal advisors regarding the tax consequences of the Award and has either done so or knowingly and voluntarily declined to do so. Additionally, each Participant acknowledges that any Option or SAR is exempt from Section 409A only if the exercise or strike price of such Option or SAR is at least equal to the “fair market value” of the Common Stock on the date of grant of such Option or SAR as determined by the Internal Revenue Service and there is no other impermissible deferral of compensation associated with the Award. Additionally, as a condition to accepting an Option or SAR, each Participant agrees to not make any claim against the Company, or any of its Officers, Directors, Employees or Affiliates in the event that the Internal Revenue Service asserts that the exercise or strike price of such Option or SAR is less than the “fair market value” of the Common Stock on the date of grant of such Option or SAR as subsequently determined by the Internal Revenue Service. (d) Withholding Indemnification. As a condition to accepting an Award, in the event that the amount of the Company’s and/or its Affiliate’s withholding obligations in connection with such Award was greater than the amount actually withheld by the Company and/or its Affiliates, each Participant agrees to indemnify and hold the Company and/or its Affiliates harmless from any failure by the Company and/or its Affiliates to withhold the proper amount. 9. MISCELLANEOUS. (a) Dividends and Dividend Equivalents. Dividends or dividend equivalents may not be paid or credited to any Awards. (b) Source of Shares. The stock issuable under the Plan will be shares of authorized but unissued or reacquired Common Stock, including shares repurchased by the Company on the open market or otherwise. (c) Use of Proceeds from Sales of Common Stock. Proceeds from the sale of shares of Common Stock pursuant to Awards will constitute general funds of the Company. (d) Corporate Action Constituting Grant of Awards. Corporate action constituting a grant by the Company of an Award to any Participant will be deemed completed as of the date of such corporate action, unless otherwise determined by the Board, regardless of when the instrument, certificate, or letter evidencing the Award is communicated to, or actually received or accepted by兆.e Participant. In the event that the corporate records (e.g., Board consents, resolutions or minutes) documenting the corporate action approving the grant contain terms (e.g., exercise price, vesting schedule or number of shares) that are inconsistent with those in the Award Agreement or related grant documents as a result of a clerical error in the Award Agreement or related grant documents, the corporate records will control and the Participant will have no legally binding right to the incorrect term in the Award Agreement or related grant documents.
在奖励项目满足条件规定前，没有参与者被视为持有任何普通股份或具有与之相关权利，且除非：(i)该参与者达到其应满足的奖励条件，如适用，并且(ii)反映该奖励普通股发行在公司纪录上。
涉及交易时，如果参与者在非豁免奖项授予的适用日期是员工或顾问之一。(i)已发生豁免奖项。以下规定适用于任何已发生豁免奖项与交易有关：(1) 如果交易也是第409A条变更控制的一部分，则收购实体不得承担、续办或替代已发生豁免奖项。在第409A条变更控制时，已发生豁免奖项的结算将自动加速，股份将立即发行以彰显已发生的豁免奖项。或者，公司可以决定让参与者获得相当于在第409A条变更控制时应发行予参与者的股份公平市值的现金结算。(2)如果交易并非也是第409A条变更控制，那么收购实体必须承担、续办或替代每个已发生的豁免奖项。已发生的豁免奖项的股份将按照若交易未发生时应发放予参与者的进度表由收购实体发放予参与者。依据收购实体的裁量，代替发放股份，收购实体可以决定在每个适用的发放日期代之以等于若交易未发生时股份的公平市值的现金支付，该市值将在交易日期确定。(ii)未发生的豁免奖项。以下规定适用于除非由董事会根据第11(e)条另行决定之外的任何未发生的豁免奖项：(1) 在发生交易时，收购实体将承担、续办或替代任何未发生的豁免奖项。除非董事会另行决定，否则任何未发生的豁免奖项将继续受到交易前适用的授予限制和没收限制的约束。未发生的豁免奖项的股份将按照若交易未发生时应发放予参与者的进度表由收购实体发放予参与者。根据收购实体的裁量，代替发放股份，收购实体可以在每个适用的发放日期代之以等于若交易未发生时股份的公平市值的现金支付，该市值将在交易日期确定。(2)如果与交易相关时，收购实体不承担、替代或续办任何未发生的豁免奖项，那么此奖项将自动终止并在交易后没有支付给任何参与者以作为此未发生的豁免奖项被取消之金额。尽管如上，董事会可能依其裁量决定在交易后加速未发生的豁免奖项的授予和结算，或者代之以等于将否则发放予参与者的股份的公平市值的现金支付作为进一步规定在第11(e)(ii)条之后。若董事会未做出相应的选择，则任何未发生的豁免奖项将在未来交易中在未经支付任何对相关受影响参与者的情况下取消。不论该交易是否也是第409A条变更控制，都将对所有未发生的豁免奖项进行上述处置。(d)非员工董事交易中的非豁免奖项处置。本第11(d)条之以下规定适用并且将取代与交易中非豁免主管奖项的处置有所抵触的任何条款。(i)如果交易同时是第409A条变更控制的一部分，则收购实体可能不得承担、续办或替代非豁免主管奖项。在第409A条变更控制时，任何非豁免主管奖项的授予和结算将自动加速，股份将立即发行以彰显非豁免主管奖项。或者，公司可以决定让参与者代之获得相当于应在第409A条变更控制时发行予参与者的股份的公平市值的现金结算，根据前述条文。(ii)如果交易并非也是第409A条变更控制的一部分，则收购实体必须承担、续办或替代非豁免主管奖项。除非董事会另行决定，否则非豁免主管奖项将继续受到任何交易前适用的授予限制和没收限制的约束。非豁免主管奖项的股份将按照若交易未发生时应发放予参与者的进度表由收购实体发放予参与者。依据收购实体的裁量，代替发放股份，收购实体可以在每个适用的发放日期代之以等于若交易未发生时股份的公平市值的现金支付，该市值将在交易日期确定。(e)如果RSU奖项是非豁免奖项，则根据此第11(e)条的规定适用并且将取代与此类非豁免奖项的处置有所抵触的协议或奖项协议：(i)董事会决定提前授予非豁免奖项的授权将不导致对于非豁免奖项相应的股份如期发放日期的加速，除非股份在适用的授予日期前授予对于第409A条的要求是合规的。(ii)公司明确保留权利在符合第409A条的要求并依据财政部法规第1.409A-3(j)(4)(ix)的任何可用豁免的情况下提前结算任何非豁免奖项。(iii)在任何非豁免奖项的条款规定其将根据要求进行结算的交易时事件的范围内，如果这需要符合第409A条的要求，触发结算的交易事件还必须构成第409A条变更控制。至于任何非豁免奖项条款规定其将在离职或连续服务终止时进行结算的范围，如果这需要符合第409A条的要求，触发结算的终止事件也必须构成离职服务事件。但如果在股份原本将在「离职服务」事件中发放予参与者的时候，该参与者受到适用于代码第409A条(a)(2)(B)(i)中的「特定雇员」的限制，此职位不予以发放，在参与者离职服务后六个月的日期之前，或如果提前，则发生在此六个月期间内的参与者死亡日期前将不会发放股份。(iv)此第11(e)条中适用于作为非豁免奖项的 RSU 奖项的结算的股份派发将旨在遵守第409A条的要求，以便对参与者发放此类非豁免奖项的股份不会触发根据第409A条附加的税负，并且任何此条件模糊之处将得到同样的解释。
307473618 v2 25. (j) “Capitalization Adjustment” 表示在采纳日后发生的与计划或任何奖励相关的普通股所做的任何变动或其他事件，并且在该变动或事件中，公司未通过合并、合并、重组、股本重整、重编公司章程、股票股利、非现金财产股利、大额非经常性现金股利、股票分割、股票逆向拆股、清算股息、股份结合、股票交换、公司治理结构变化或任何类似的权益重组交易，而收到公司有任何代价。︰
（bb）“《换股法》即1934年修订版本的证券交易法，和在此之下发布的规则和法规。
（cc）“《换股法》人士”指的是除了公司或任何子公司，任何员工福利计划或公司或任何子公司的受托人或其他受托人持有公司股票的任何自然人、实体或“集团”（依据《换股法》第13（d）条或第14（d）条的意义），但“《换股法》人士”不包括（i）公司或任何子公司，（ii）公司的员工福利计划或任何子公司或持有公司员工福利计划证券的受托人或其他受托人，（iii）临时持有证券的承销商，根据这些证券的公开注册发行，（iv）直接或间接是由公司股东按其对公司股份的比例持有相同比例的实体所有，或（v）任何自然人、实体或在有效日期时是公司证券的业主(不论直接或间接)，拥有公司当时已发行证券的合计表决权的50%以上。
（dd）“公允市值”在任何日期指的是，除非董事会另行决定，普通股的价值（依据每股或总体基准，视情况而定）如下确定： （i）如果普通股在任何建立的证券交易所上市或在任何建立的市场上交易，公允市值将是在确定日期报导于其认为可靠的来源的该股的按照该交易所或市场（或普通股交易量最大的交易所或市场）报价的收盘价，报价此股票，当天报价，报告于董事会认为可靠的来源。 （ii）如果在确定日没有普通股的收盘价，那么公允市值将是上一次该报价存在的日期的收盘价。 （iii）在缺乏普通股的这种交易所或市场的情况下，或者如果董事会另行决定，公允市值将由董事会按 409A条款和422 以诚实良好信奉的方式决定。
（ee）“完全价值奖”意味著（i）根据以往计划授予的股票奖或（ii）奖，每种都不是增值奖金。
按照普遍认可的会计准则，需要记录的商誉和无形资产损失；及排除根据接受提交的时间和/或获得美国食品药品监督管理局或任何其他规管机构审查和/或批准的影响。此外，董事会保留自行裁定，以确定选择用于财报季间的绩效标准的计算方式，以及在实现任何业绩目标后减少或取消应当支付的报酬或经济利益。部分实现任何业绩目标可能导致根据适用授予协议或绩效奖项的书面条件，进行与实现程度相对应的支付或兑现。